BRIEF-XTL Biopharmaceuticals expands clinical advisory board with two experts in rheumatology
BRIEF-ED says conversion of 7th and 8th series convertible bonds into shares
* Says 2.5 billion won worth of its 7th series unregistered and unsecured private convertible bonds have been converted into 920,132 shares of the company, at 2,717 won/share, as of Feb. 15